Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to identify subjects who are highly sensitized with antibodies. It is difficult for these patients to find suitable kidneys. We propose to treat such patients to decrease the antibodies in such a way, that it may become possible to safely transplant kidneys into them.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago
• Treatments: Antibodies; Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

1. Eighteen years or older,

2. On the waiting list for a kidney transplant list

3. On hemodialysis or peritoneal dialysis

Exclusion Criteria:

1. Pregnant woman

2. Patients who need ongoing blood products

3. Patients with failed organs having active rejection

4. Other therapies to decrease PRA

5. Patients listed for multi-organ transplants (other than kidney-pancreas)